Viking Therapeutics appoints Dorothy Gemmell to board effective immediately

The clinical-stage biotech said Gemmell brings more than 25 years of healthcare, digital health and commercialization experience as Viking advances obesity candidate VK2735.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.